Objective:To explore the effects of different courses of Bifidobacterium combined with bismuth on the eradication rate, ulcer healing rate and adverse reactions in the initial eradication treatment of Helicobacter pylori positive gastric ulcer patients.Methods:From September 2018 to September 2021, 219 patients with gastric ulcer were selected from the outpatient department of gastroenterology department of Kailuan General Hospital Affiliated,all of whom were positive for 13C or 14C-urea breath test and were not treated with Helicobacter pylori eradication. Group A, B and C were randomly divided by Excel, Group A was the control group (73 patients): 14-day bismuth quadruple therapy (Eprazole + colloidal bismuth pectin + amoxicillin + furazolidone); group B (73 patients): 7 days Bifidobacterium tetravaccine tablets (live) was given in the second week of treatment in group A; group C (73 patients): Bifidobacterium tetravaccine tablets (live) was given 14 days on the basis of treatment in group A. 13C or 14C-urea breath test and gastroscope were reexamined after all treatments, to compare the eradication rate, ulcer healing rate and the incidence of adverse reactions.Results:The eradication rates in three groups were 90.8%(59/65), 91.2% (62/68)and 91.0%(61/67) respectively, there was no significant difference among the three groups (χ 2=0.01, P=0.997). The ulcer healing rate in three groups were 93.8%(61/65), 94.1%(64/68) and 95.5%(64/67) respectively, group B and group C were compared with group A, and the difference was not statistically significant(group B: group A P=1.000, group C: group A P=0.716).The incidence of adverse reactions in three groups was 21.4%(15/70), 7.1%(5/70) and 7.0%(5/71) respectively, the difference was statistically significant (χ 2=9.21, P=0.010). The incidence of adverse reactions in group B and C was significantly lower than that in group A (group B: group A χ 2=5.83, P=0.016; group C: groups A χ 2=5.99, P=0.014). Compare means of measurement data among the three groups use analysis of variance. Chi square test, Fisher exact probability method and split chi square test were used to compare the three groups of counting data. Conclusion:14-day Bifidobacterium tetravaccine tablets (live) and the second half of the treatment lasted for 7-day Bifidobacterium Bifidobacterium tetravaccine tablets (live), they are combined separately with bismuth quadruple therapy in the first eradication of Helicobacter pylori positive gastric ulcer patients can significantly reduce adverse reactions, but Bifidobacterium tetravaccine tablets (live) could not significantly improve the eradication rate, and had no promoting effect on the healing of gastric ulcer.

Objective:To explore the effect of the eradication rate and adverse reactions of different courses of Bifidobacterium combined with quadruple therapy containing furazolidone and tetracycline for rescue eradication of Helicobacter pylori.Methods:From December 2016 to May 2019, 348 patients with chronic gastritis who failed to eradicate Hp for the first time were selected from the outpatient department of digestive medicine of Kailuan General Hospital affiliated to North China University of Technology.Group A, B and C were randomly divided by Excel, Group A(116 patients): 14-day quadruple therapy (Eprazole+ colloidal bismuth pectin+ furazolidone + tetracycline); group B(116 patients): Bifidobacterium was given 14 days on the basis of treatment in group A; group C(116 patients): 7 days Bifidobacterium was given in the second week of treatment in group A 4 weeks after the end of eradication treatment, 14 C urea breath test was reexamined, to compare the eradication rate and the incidence of adverse reactions.Results:The eradication rates were 80.2%, 84.5% and 82.3% respectively according to intention treatment.The eradication rates were 88.6%, 90.7% and 89.7%, respectively according to perprotocol.There was no significant difference between the three groups(according to intention to treat analysis: χ 2=0.755, P=0.685; according to the perprotocol analysis: χ 2=0.271, P=0.873). The incidence of adverse reactions in three groups was 16.4%, 6.3% and 7.3% respectively, the difference was statistically significant(χ 2=7.561, P=0.023). Group B was significantly lower than group A(χ 2=5.570, P=0.017), the difference was statistically significant, but there was no statistically significant difference between group C and group A(χ 2=4.362, P=0.037). Conclusion:After 14 days of Bifidobacterium tetrad live tablet assisted with tetrad therapy containing furazolidone and tetracycline, the adverse reactions could be significantly reduced, but Bifidobacterium could not significantly improve the eradication rate.